Vertex Pharmaceuticals Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 1,211,975 1,527,042 1,410,626 143,370
Cost of Revenue 130,277 279,885 80,505 12,730
Gross Profit 1,081,698 1,247,157 1,330,121 130,640
Operating Expenses
Research and Development 918,783 806,185 707,706 637,416
Sales, General and Admin. 362,342 436,796 400,721 187,800
Non-Recurring Items 704,021 1,844 107,874 1,501
Other - - - -
Operating Income (903,448) 2,332 113,820 (696,077)
Income From Continuing Operations
Add'l Income/Expense Items (49,939) 309 (15,694) (39,274)
Earnings Before Interest and Tax (953,387) 2,641 98,126 (735,351)
Interest Expense 22,730 15,022 37,681 19,275
Earnings Before Tax (976,117) (12,381) 60,445 (754,626)
Income Tax (288,567) 38,754 19,266 -
Minority Interest (242,522) 55,897 11,605 -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (445,028) (107,032) 29,574 (754,626)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (445,028) (107,032) 29,574 (754,626)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (445,028) (107,032) 29,574 (754,626)